Keyword: J. Michael Pearson
A former Valeant executive suspected an illicit relationship between a colleague and mail order pharmacy Philidor, he testified.
Valeant is getting a new name and stock ticker to press ahead after its storied downfall.
The murky relationship between Valeant and now-defunct specialty pharmacy Philidor will spotlight a not-so-flattering chapter in its recent history.
After paying $1 billion for Sprout and its controversial female libido pill Addyi, Valeant is giving up.
A mutual fund that says it lost a mind-boggling $80 billion investing in Valeant alleges in a lawsuit that Valeant was a criminal enterprise.
Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may not be so easy.
Former Valeant CEO J. Michael Pearson says the company owes him even more than it's already shelled out in severance and consulting fees—and he’s suing to collect.
Bill Ackman’s Valeant chapter is finally coming to a painful close. The activist investor bailed out of the company, selling his 27.2M shares for just about $11 apiece.
Valeant has wrapped up a couple of shareholder lawsuits it inherited with its purchase of Salix. But it’s now millions of dollars deeper in the hole.